Developing a Prognostic Information System for Personalized Care in Real Time

Context: Electronic medical records hold promise to transform clinical practice. However, technological and other barriers may preclude using them to guide care in real time. We used the Virtual Data Warehouse (VDW) to develop a tool that enables physicians to generate real-time, personalized prognostic information about survival after cancer. Case description: Patients with cancer often ask their oncologists, “Have you ever seen a patient like me?” To help oncologists answer this question, we developed a prototype Prognostic Information System (PRISM), a web-based tool that gathers data about the index patient from Kaiser Permanente’s clinical information systems, selects a historical cohort of similar patients, and displays the survival curve of the similar patients relative to key points in their treatment course. Findings and major themes: The prototype was developed by a multidisciplinary team with expertise in oncology, research, and technology. We have completed two rounds of user testing and refinement. Successful development rested on: (1) executive support and a clinical champion; (2) collaboration among experts from multiple disciplines; (3) starting with simple cases rather than ambitious ones; (4) extensive research experience with the Virtual Data Warehouse, related databases, and an existing query tool; and (5) following agile software development principles, especially iterative user testing. Conclusion: Clinical data stored in health care systems’ electronic medical records can be used to personalize clinical care in real time. Development of prognostic information systems can be accelerated by collaborations among researchers, technology specialists, and clinicians and by use of existing technology like the Virtual Data Warehouse.

[1]  Su-Xu Yuan,et al.  Prognostic factors in patients with pancreatic cancer. , 2012, Experimental and therapeutic medicine.

[2]  James M Robins,et al.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.

[3]  G. Hortobagyi,et al.  Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Martino,et al.  Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. , 2000, The New England journal of medicine.

[5]  Andrew Nguyen,et al.  ARTIFICIAL INTELLIGENCE FOR THE REAL WORLD , 2023, International Research Journal of Modernization in Engineering Technology and Science.

[6]  H. Welch,et al.  Presumed benefit: lessons from the American experience with marrow transplantation for breast cancer , 2002, British medical journal.

[7]  Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma , 2017, Scientific Reports.

[8]  J. Rassen,et al.  Confounding Control in Healthcare Database Research: Challenges and Potential Approaches , 2010, Medical care.

[9]  Jeffrey E. Lee,et al.  Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer. , 2012, Archives of surgery.

[10]  M. Lippman,et al.  High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. , 2000, The New England journal of medicine.

[11]  Amela,et al.  CONVENTIONAL-DOSE CHEMOTHERAPY COMPARED WITH HIGH-DOSE CHEMOTHERAPY PLUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR METASTATIC BREAST CANCER , 2000 .

[12]  U. Chettipally,et al.  Optimizing Clinical Decision Support in the Electronic Health Record , 2016, Applied Clinical Informatics.

[13]  R. Gale,et al.  Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants. , 1988, Annals of internal medicine.

[14]  Eileen M. Walsh,et al.  A Quantitative, Risk-Based Approach to the Management of Neonatal Early-Onset Sepsis , 2017, JAMA pediatrics.

[15]  J. Frankovich,et al.  Evidence-based medicine in the EMR era. , 2011, The New England journal of medicine.

[16]  Patricia Kipnis,et al.  Risk-adjusting Hospital Mortality Using a Comprehensive Electronic Record in an Integrated Health Care Delivery System , 2013, Medical care.

[17]  Ewout W. Steyerberg,et al.  Big Data and Predictive Analytics: Recalibrating Expectations , 2018, JAMA.